Photo taken from Deridre Kelly/X
Oct 4, 2024, 09:43
Deridre Kelly: Ph2 Capmatinib in METex14 NSCLC
Deridre Kelly, Professor of Paediatric Hepatology at the University of Birmingham, sharen on X:
“New The Lancet Oncology – Phase2 Capmatinib in METex14 NSCLC
Objective response rate: 68%
Progression-free survival: 12.5 months
Overall survival: 21.4 months (1st-line), 16.8 months (later lines)
Adverse Events: edema 47%, nausea 35%, creatinine 21%, vomiting 20%
METex14 key biomarker for METi.”
Source: Deridre Kelly/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 21:37
Nov 15, 2024, 21:26
Nov 15, 2024, 21:09
Nov 15, 2024, 21:05
Nov 15, 2024, 21:03
Nov 15, 2024, 21:02
Nov 15, 2024, 20:28
Nov 15, 2024, 19:31
Nov 15, 2024, 17:47
Nov 15, 2024, 17:45